GlaxoSmithKline Cutting Up to 720 Jobs at European Vaccine Facility
In advance of its split into two companies, pharmaceutical giant GlaxoSmithKline (NYSE: GSK) announced it will cut as many as 720 workers from its vaccine production facility in Belgium. In addition to these layoffs, which are part of its two-year restructuring program, the company said it will decline to renew the contracts of 215 temporary employees.
Most of the employees losing their jobs work in manufacturing, research and development, and global support positions. The majority are managers.
Image source: GlaxoSmithKline
Source Fool.com
